Following a full submission
AWMSG advice |
||
| Status: Not recommended | ||
Idursulfase (Elaprase®) should not be recommended for use within NHS Wales for the long-term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). The clinical and cost effectiveness data presented was not sufficient for AWMSG to recommend its use. |
||
|
||
Medicine details |
||
| Medicine name | idursulfase (Elaprase®) | |
| Formulation | 2 mg/ml concentrate for solution for infusion | |
| Reference number | 162 | |
| Indication | Long term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II) |
|
| Company | Shire Human Genetic Therapies | |
| BNF chapter | Nutrition & blood | |
| Submission type | Full | |
| Status | Not recommended | |
| Advice number | 1207 | |
| NMG meeting date | 12/09/2007 | |
| AWMSG meeting date | 18/10/2007 | |
| Ratification by Welsh Government | 15/11/2007 | |
| Date of issue | 20/11/2007 | |